• Molecular NameCefacetrile
  • Synonym7-Cyanacetylamino-cephalosporansaeure; Cefacetrilo [inn-spanish]; Cefacetrilum [inn-latin]; Cephacetrile
  • Weight339.328
  • Drugbank_IDDB01414
  • ACS_NO10206-21-0
  • Show 3D model
  • LogP (experiment)0.35
  • LogP (predicted, AB/LogP v2.0)-0.78
  • pka1.5, 7.2
  • LogD (pH=7, predicted)-4.77
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.47
  • LogSw (predicted, AB/LogsW2.0)85.39
  • Sw (mg/ml) (predicted, ACD/Labs)0.16
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds7
  • TPSA162.1
  • StatusFDA approved
  • AdministrationIntravenous, intramuscular
  • PharmacologyA broad-spectrum first generation cephalosporin antibiotic effective in Gram-positive and Gram-negative bacterial infections. It is a bacteriostatic antibiotic.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding25.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life0.5~1 h; 2.3~2.8 h in patients with the complete absence of renal function. Serum, 0.6 to 0.9 h; slightly prolonged in patients with renal impairment.
  • ExcretionRenal (72%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A